Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

Sean D Sullivan, Rafael Alfonso-Cristancho, Chris Conner, Mette Hammer, Lawrence Blonde, Sean D Sullivan, Rafael Alfonso-Cristancho, Chris Conner, Mette Hammer, Lawrence Blonde

Abstract

Background: Poor control of type 2 diabetes results in substantial long-term consequences. Studies of new diabetes treatments are rarely designed to assess mortality, complication rates and costs. We sought to estimate the long-term consequences of liraglutide and rosiglitazone both added to glimepiride.

Methods: To estimate long-term clinical and economic consequences, we used the CORE diabetes model, a validated cohort model that uses epidemiologic data from long-term clinical trials to simulate morbidity, mortality and costs of diabetes. Clinical data were extracted from the LEAD-1 trial evaluating two doses (1.2 mg and 1.8 mg) of a once daily GLP-1 analog liraglutide, or rosiglitazone 4 mg, on a background of glimepiride in type 2 diabetes. CORE was calibrated to the LEAD-1 baseline patient characteristics. Survival, cumulative incidence of cardiovascular, ocular and renal events and healthcare costs were estimated over three periods: 10, 20 and 30 years.

Results: In a hypothetical cohort of 5000 patients per treatment followed for 30 years, liraglutide 1.2 mg and 1.8 mg had higher survival rates compared to the group treated with rosiglitazone (15.0% and 16.0% vs. 12.6% after 30 years), and fewer cardiovascular, renal, and ocular events. Cardiovascular death rates after 30 years were 69.7%, 68.4% and 72.5%, for liraglutide 1.2 mg, 1.8 mg, and rosiglitazone, respectively. First and recurrent amputations were lower in the rosiglitazone group, probably due to a 'survival paradox' in the liraglutide arms (number of events: 565, 529, and 507, respectively). Overall cumulative costs per patient, were lower in both liraglutide groups compared to rosiglitazone (US$38,963, $39,239, and $40,401 for liraglutide 1.2 mg, 1.8 mg, and rosiglitazone, respectively), mainly driven by the costs of cardiovascular events in all groups.

Conclusion: Using data from LEAD-1 and epidemiologic evidence from the CORE diabetes model, projected rates of mortality, diabetes complications and healthcare costs over the long term favor liraglutide plus glimepiride over rosiglitazone plus glimepiride.

Trial registration: LEAD-1 NCT00318422; LEAD-2 NCT00318461; LEAD-3 NCT00333151; LEAD-5 NCT00331851; LEAD-6 NCT00518882.

Trial registration: ClinicalTrials.gov NCT00318422 NCT00318461 NCT00331851 NCT00333151 NCT00518882 NCT00294723.

Figures

Figure 1
Figure 1
Breakdown of medical costs. CVD, cardiovascular disease.

References

    1. UKPDS Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853. doi: 10.1016/S0140-6736(98)07019-6.
    1. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443. doi: 10.1056/NEJMoa066224.
    1. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest. 2006;116:1756–1760. doi: 10.1172/JCI29189.
    1. World Health Organization 2008.
    1. CDC National Center for Chronic Disease Prevention and Health Promotion 2007 National Diabetes Fact Sheet
    1. American Diabetes Association Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31:S1–S2. doi: 10.2337/dc08-S001.
    1. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050. Diabetes Care. 2006;29:2114–2116. doi: 10.2337/dc06-1136.
    1. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care. 2002;25:476–481. doi: 10.2337/diacare.25.3.476.
    1. Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care. 2002;25:482–486. doi: 10.2337/diacare.25.3.482.
    1. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther. 2003;25:1017–1038. doi: 10.1016/S0149-2918(03)80122-4.
    1. Gilmer TP, O'Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, Solberg LI. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005;28:59–64. doi: 10.2337/diacare.28.1.59.
    1. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672–676. doi: 10.1016/0002-8703(90)90026-T.
    1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234. doi: 10.1056/NEJM199807233390404.
    1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444. doi: 10.2337/diacare.16.2.434.
    1. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014–1019.
    1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591. doi: 10.1056/NEJMoa0706245.
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. doi: 10.1056/NEJMoa0806470.
    1. ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572. doi: 10.1056/NEJMoa0802987.
    1. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) Med Decis Making. 2002;22:340–349. doi: 10.1177/027298902400448902.
    1. Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health. 2001;4:392–400. doi: 10.1046/j.1524-4733.2001.45029.x.
    1. Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care. 2007;30:2478–2483. doi: 10.2337/dc07-0499.
    1. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, the VADT Investigators Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360:129–139. doi: 10.1056/NEJMoa0808431.
    1. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS, American Diabetes Association; American College of Cardiology Foundation; American Heart Association Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187–192. doi: 10.2337/dc08-9026.
    1. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges J-P, Verhoeven R, Buganova I, Madsbad S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608–1610. doi: 10.2337/dc06-2593.
    1. Marre M, Shaw J, Brandle M, Wan Bebakar W, Kamaruddin N, Strand J, Zdravkovic M, Le-Thi TD, Colagiuri S, on behalf of the LEAD-1 SU study group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabet Med. 2009;26:268–278. doi: 10.1111/j.1464-5491.2009.02666.x.
    1. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, During M, Zdravkovic , Matthews D. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care. 2009;32:84–90. doi: 10.2337/dc08-1355.
    1. Garber A, Henry R, Ratner R, Garcia-Hernadez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovc M, Bode B, for the LEAD-3 (Mono) Study Group Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–481. doi: 10.1016/S0140-6736(08)61246-5.
    1. Zinman B, Gerich J, Buse J, Lewin A, Schwartz SL, Raskin P, Hale PM, Zdravkovic M, Blonde L. Effect of the GLP-1 analog liraglutide on glycemic control and weight reduction in patients on metformin and rosiglitazone: a randomized double-blind placebo-controlled trial [abstract] Diabetologia. 2008;51:S359.
    1. Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic NM, Antic S, Zdravkovic M, Ravn GM, Simo R. Significantly better glycaemic control/weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as add-on to metformin + sulphonylurea in type 2 diabetes [abstract] Diabetologia. 2008;51:S68.
    1. Blonde L, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett J, Zychma M, Buse J. Liraglutide: superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes [abstract] Can J Diabetes. 2008;32:A107.
    1. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20:S5–S26. doi: 10.1185/030079904X1980.
    1. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20:S27–S40. doi: 10.1185/030079904X2006.
    1. Brändle M, Herman WH. The CORE Diabetes Model. Curr Med Res Opin. 2004;20:S1–S3. doi: 10.1185/030079904X1962.
    1. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Hayes C, Oglesby A, Spinas GA. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin. 2004;20:S53–S58. doi: 10.1185/030079903125002611.
    1. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, Hayes C, Spinas GA. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model. Curr Med Res Opin. 2004;20:S59–S66. doi: 10.1185/030079904X2024.
    1. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabet Med. 2005;22:1239–45. doi: 10.1111/j.1464-5491.2005.01576.x.
    1. Watkins JB, Minshall ME, Sullivan SD. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience. J Manag Care Pharm. 2006;12:726–35.
    1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective, observational study. BMJ. 2000;321:405–412. doi: 10.1136/bmj.321.7258.405.
    1. Saaddine JB, Cadwell B, Gregg EW, Engelgau MW, Vinicor F, Imperatore G, Narayan V. Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 1988–2002. Ann Intern Med. 2006;144:465–474.
    1. Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health. 2008;11:22–33.
    1. Tarn T, Smith M. Pharmacoeconomic Guidelines Around the World. ISPOR Connections. 2004;1:5–15.
    1. Fleming T, Ed . 2006 Drug Topics Red Book. 11. Thomson PDR, Montvale, NJ, USA; 2006.
    1. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: A cost-effectiveness analysis. Dermatologic Surgery. 2001;27:347–351. doi: 10.1046/j.1524-4725.2001.00280.x.
    1. DRG Guidebook . A Comprehensive Resource to the DRG Classification System. 17. St Anthony Press; 2001.
    1. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care. 2003;26:2305–2310. doi: 10.2337/diacare.26.8.2305.
    1. American Diabetes Association Consensus Panel Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004;27:2262–2265. doi: 10.2337/diacare.27.9.2262.
    1. Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD, for The RECORD Study Group Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study) Cardiovascular Diabetology. 2008;7:10. doi: 10.1186/1475-2840-7-10.
    1. The Mt Hood 4 Modeling Group Computer Modeling of Diabetes and Its Complications. Diabetes Care. 2007;30:1638–1646. doi: 10.2337/dc07-9919.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する